Loading...
Market
What will be the next significant partnership or agreement for Seelos Therapeutics by December 31, 2025?
2
Resolution / Starting Odds
Pharmaceutical company • 25%
Government agency • 25%
Research institution • 25%
Other • 25%
Press releases from Seelos Therapeutics
Story
Seelos Therapeutics ($SEEL) Signs Agreement with USAMMDA to Evaluate SLS-002 for PTSD, Stock Surges 115.8%
Sep 24, 2024, 12:38 PM
Seelos Therapeutics ($SEEL) has announced the signing of a Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate its intranasal ketamine, SLS-002, for the treatment of PTSD. This agreement includes the inclusion of SLS-002 in the U.S. Department of Defense’s M-PACT trial, which will begin dosing in the fourth quarter of 2024. The Phase II trial will assess the safety, efficacy, and tolerability of SLS-002 in active-duty service members and veterans. Following this announcement, Seelos Therapeutics' stock surged by 115.8% in pre-market trading.
View original story
Similar markets
Launch a new drug • 25%
Enter a new partnership • 25%
Expand into new markets • 25%
No major changes • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Secures funding only • 25%
Secures partnership deal only • 25%
Secures both funding and partnership deal • 25%
Secures neither • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%